Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Entrada Therapeutics's FCF Margin % or its related term are showing as below:
TRDA'
s FCF Margin % Range Over the Past 10 Years
Min: -2294.2 Med: -21.21 Max: 104.01
Current: -2294.2
During the past 7 years, the highest FCF Margin % of Entrada Therapeutics was 104.01%. The lowest was -2294.20%. And the median was -21.21%.
TRDA's FCF Margin % is ranked worse than 85.26% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs TRDA: -2294.20
Entrada Therapeutics FCF Margin % Related Terms
Entrada Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entrada Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (TRDA) has a FCF Margin % of -4,770.17% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Entrada Therapeutics and its competitors. According to the industry distribution chart, Entrada Therapeutics ranks #810 out of 950 companies in the Biotechnology industry, placing it in the top 85.3%.
Is Entrada Therapeutics' FCF Margin % too high?
Entrada Therapeutics' current FCF Margin % is -4,770.17%. Based on the distribution chart, Entrada Therapeutics ranks #810 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Entrada Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' FCF Margin % compare to NMRA and MGNX?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #810 out of 950 companies for FCF Margin %. This places Entrada Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Entrada Therapeutics and its competitors. Entrada Therapeutics's current FCF Margin % is -4,770.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $5.85 — trading 451.9% above its estimated fair value. The current FCF Margin % is -4,770.17%. Entrada Therapeutics' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current FCF Margin % is -4,770.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $5.85 is trading 451.9% above its estimated GF Value™ of $1.06.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
FCF Margin %: -4,770.17%
GF Value™: $1.06 vs. price of $5.85 (451.9% above fair value)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
35GF Score
Get the complete analysis for TRDA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
